
Paroxetine
Paroxetine is an established SSRI. A large network meta-analysis found it more effective than placebo for adult depression, and placebo-controlled trials support it for social anxiety disorder, PTSD and, at a low 7.5 mg dose, menopausal hot flashes. A reanalysis of a trial in adolescents found no benefit and more harms. St. John's wort is the critical supplement interaction; cannabis is a high-severity concern and saffron a low one.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with depression, OCD, panic disorder, social anxiety disorder, generalized anxiety disorder or PTSD whose prescriber recommends an SSRI, and postmenopausal women with moderate to severe hot flashes (low-dose Brisdelle)
Common dosing range
Set by your prescriber. The Paxil label starts at 20 mg once daily for depression, OCD, social anxiety and PTSD, 10 mg for panic disorder and generalized anxiety disorder, with maximums of 50 to 60 mg a day depending on the condition; older adults and people with severe kidney or liver impairment start at 10 mg with a 40 mg maximum. Brisdelle is 7.5 mg once daily
When to expect effects
Depression trials in the network meta-analysis were acute trials of weeks; social anxiety and PTSD trials lasted 11 to 12 weeks; hot flashes fell by week 4
Watch out for
Boxed warning for suicidal thoughts and behaviors in children, teens and young adults. Never combine with MAO inhibitors or St. John's wort without your prescriber. Raises bleeding risk with aspirin, NSAIDs and blood thinners. First-trimester use is linked to a less than 2-fold rise in heart defects. Do not stop suddenly: the label recommends a gradual reduction
What is it
Paroxetine is a prescription antidepressant of the selective serotonin reuptake inhibitor (SSRI) class, sold as generic tablets, Paxil tablets and Paxil CR extended-release tablets. The Paxil label approves it in adults for major depressive disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder and posttraumatic stress disorder. A low-dose capsule, Brisdelle (paroxetine mesylate 7.5 mg), is approved only for moderate to severe hot flashes of menopause, not for any psychiatric condition. Paroxetine is not approved for children. Its boxed warning covers suicidal thoughts and behaviors in young people. St. John's wort is the critical supplement interaction, cannabis a high-severity one and saffron a low-severity one.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
major depressive disorder in adults Good Evidence | Modest; response odds about 1.4 to 2.1 times placebo across antidepressants | Adults with major depressive disorder, without bipolar or psychotic features | Acute treatment trials lasting weeks |
social anxiety disorder Good Evidence | Large; about 31 more responders per 100 people than placebo | Adults with the generalized type of social anxiety disorder | Measured at the end of 11 weeks of active treatment |
posttraumatic stress disorder (PTSD) Good Evidence | Statistically significant improvement over placebo at 20 and 40 mg a day; the abstract does not give the size | Adults with chronic PTSD | Measured over 12 weeks |
menopausal hot flashes (low-dose 7.5 mg) Good Evidence | Modest; significant reductions in frequency versus placebo (exact sizes not in the abstract) | Postmenopausal women with moderate to severe hot flashes who cannot or prefer not to use hormones | By week 4 |
major depression in adolescents Good Evidence | None; 1.6 points more improvement than placebo, not significant, with more harms | Not applicable: no benefit was found in adolescents | Measured at 8 weeks |
major depressive disorder in adults
- Effect
- Modest; response odds about 1.4 to 2.1 times placebo across antidepressants
- Best fit
- Adults with major depressive disorder, without bipolar or psychotic features
- Time
- Acute treatment trials lasting weeks
social anxiety disorder
- Effect
- Large; about 31 more responders per 100 people than placebo
- Best fit
- Adults with the generalized type of social anxiety disorder
- Time
- Measured at the end of 11 weeks of active treatment
posttraumatic stress disorder (PTSD)
- Effect
- Statistically significant improvement over placebo at 20 and 40 mg a day; the abstract does not give the size
- Best fit
- Adults with chronic PTSD
- Time
- Measured over 12 weeks
menopausal hot flashes (low-dose 7.5 mg)
- Effect
- Modest; significant reductions in frequency versus placebo (exact sizes not in the abstract)
- Best fit
- Postmenopausal women with moderate to severe hot flashes who cannot or prefer not to use hormones
- Time
- By week 4
major depression in adolescents
- Effect
- None; 1.6 points more improvement than placebo, not significant, with more harms
- Best fit
- Not applicable: no benefit was found in adolescents
- Time
- Measured at 8 weeks
Evidence for 5 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
major depressive disorder in adults
Disease adjunctA 2018 network meta-analysis of 522 double-blind trials with 116,477 adults found that all 21 antidepressants studied, including paroxetine, were more effective than placebo for acute treatment of major depression, with odds ratios from 1.37 to 2.13. In head-to-head trials, paroxetine was among the drugs that were more effective than other antidepressants. The authors rated the certainty of evidence moderate to very low. People with bipolar, psychotic or treatment-resistant depression were largely excluded.
Bottom line: Paroxetine works better than placebo for adult depression and did well in head-to-head comparisons.
social anxiety disorder
Disease adjunctIn a 12-week randomized, double-blind trial at 14 centers in the US and Canada, 187 adults with generalized social phobia received paroxetine (20 to 50 mg a day) or placebo. At the end, 55.0% on paroxetine were much or very much improved versus 23.9% on placebo, and Liebowitz Social Anxiety Scale scores fell by 39.1% versus 17.4%. The trial was short and did not test long-term use.
Bottom line: Paroxetine roughly doubled the share of people with social anxiety who improved over 11 weeks.
posttraumatic stress disorder (PTSD)
Disease adjunctIn a 12-week fixed-dose trial, 551 outpatients with chronic PTSD were randomized to placebo, paroxetine 20 mg or paroxetine 40 mg a day. Both doses improved the main PTSD scale and global improvement more than placebo, and helped all three symptom clusters (re-experiencing, avoidance and numbing, and hyperarousal), social and work impairment, and depression. Benefit did not vary by sex, trauma type, time since trauma or baseline severity, and both doses were well tolerated.
Bottom line: Paroxetine 20 or 40 mg a day eased chronic PTSD symptoms more than placebo over 12 weeks.
menopausal hot flashes (low-dose 7.5 mg)
Disease adjunctTwo multicenter, double-blind trials lasting 12 and 24 weeks randomized 1,184 postmenopausal women with moderate to severe hot flashes to paroxetine 7.5 mg once daily or placebo. In both trials paroxetine reduced the weekly number of hot flashes more than placebo at week 4 and week 12, and the benefit persisted through 24 weeks. Severity also fell more in most comparisons. Most side effects were mild or moderate. This low dose is the Brisdelle product, not the doses used for depression.
Bottom line: Low-dose paroxetine reduced menopausal hot flashes more than placebo in two large trials.
major depression in adolescents
No benefit foundA 2015 reanalysis of the full data from Study 329, an 8-week randomized trial in 275 adolescents with major depression at 12 North American centers, found paroxetine (20 to 40 mg a day) no better than placebo on any prespecified primary or secondary outcome: Hamilton depression scores fell by 10.7 points with paroxetine and 9.1 with placebo. It found clinically significant increases in harms with paroxetine, including suicidal thinking and behavior. The current Paxil label states that effectiveness in pediatric depression was not shown in three placebo-controlled trials.
Bottom line: Paroxetine did not help depressed adolescents in Study 329 and increased harms; it is not approved for children.
How it works
How to take it
What to track
Bottom line: Your prescriber sets the dose; take it once daily in the morning, keep serotonin-boosting supplements out unless your prescriber agrees, and never stop suddenly on your own.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Suicidal thoughts and behaviors (boxed warning). In pooled trials, antidepressants increased these in people under 25 (14 extra cases per 1,000 under 18 and 5 per 1,000 aged 18 to 24); everyone taking paroxetine should be watched for worsening mood, especially in the first months and after dose changes.
Serotonin syndrome, a potentially life-threatening reaction, especially with other serotonergic products (triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, methadone, tryptophan, buspirone, amphetamines, St. John's wort) or MAO inhibitors; it can also occur with paroxetine alone.
Fetal harm: first-trimester exposure is associated with a less than 2-fold increase in cardiovascular malformations, and SSRI exposure later in pregnancy with persistent pulmonary hypertension of the newborn and newborn complications.
Higher risk of bleeding, from bruising and nosebleeds to life-threatening hemorrhage, greater with aspirin, NSAIDs, other antiplatelet drugs, warfarin or other anticoagulants.
Dangerous heart rhythm changes when combined with QT-prolonging drugs that are cleared by CYP2D6, because paroxetine strongly blocks that enzyme (contraindicated combination).
Discontinuation symptoms after stopping, especially abruptly: nausea, sweating, irritability, agitation, dizziness, electric-shock sensations, anxiety, confusion, headache, insomnia and seizures.
Activation of mania or hypomania in people with bipolar disorder, seizures (0.1% in trials), angle-closure glaucoma in people with untreated narrow eye angles, low blood sodium (sometimes below 110 mmol/L), sexual dysfunction, possible fracture risk, and possibly reduced effectiveness of tamoxifen.
Who should avoid it
- People taking an MAO inhibitor or within 14 days of stopping one (including linezolid or intravenous methylene blue); at least 14 days must also pass after stopping paroxetine before starting an MAOI
- People taking drugs that prolong the QTc interval and are CYP2D6 substrates, and people with known allergy to paroxetine or its ingredients (reactions have included anaphylaxis, angioedema and Stevens-Johnson syndrome)
- Children and teens: Paxil is not approved for pediatric patients, and three placebo-controlled trials did not show effectiveness for pediatric depression
- People taking tamoxifen for breast cancer: the label says prescribers should consider an antidepressant with little or no CYP2D6 inhibition instead
Pregnancy & breastfeeding
Pregnancy: the Paxil label says paroxetine can cause fetal harm. First-trimester exposure is associated with a less than 2-fold increase in cardiovascular malformations, so for women planning a pregnancy or in the first trimester it should be started only after considering other treatment options. SSRI exposure, particularly in the month before delivery, is associated with a less than 2-fold higher risk of heavy bleeding after birth, later exposure with persistent pulmonary hypertension of the newborn, and babies exposed late in the third trimester have needed prolonged hospital care, breathing support or tube feeding. Women who stop antidepressants during pregnancy are more likely to relapse, so the risks of untreated depression also count. A pregnancy registry for antidepressants collects outcomes. Breastfeeding: paroxetine passes into breast milk (relative infant doses of 0.4% to 2.2%), and there are reports of agitation, irritability, poor feeding and poor weight gain in exposed infants. The label says to weigh the benefits of breastfeeding against the mother's need for treatment and to monitor the infant for these signs.
Interactions
The Paxil label lists St. John's wort among serotonergic products that increase the risk of serotonin syndrome, a potentially life-threatening reaction, when combined with paroxetine, and a systematic review of St. John's wort interactions identified possible serotonin-related interactions with SSRIs. Do not combine them unless your prescriber advises it, check mood-support teas and blends for Hypericum, and seek emergency care for agitation, tremor, fever, fast heartbeat, heavy sweating or muscle stiffness. Do not stop paroxetine on your own.
The Paxil label says combining paroxetine with tryptophan, the amino acid the body turns into serotonin, increases the risk of serotonin syndrome, a potentially life-threatening reaction, and the label for Brisdelle (low-dose paroxetine) says headache, nausea, sweating and dizziness have been reported when tryptophan was given with paroxetine and that the combination is not recommended. No serotonin syndrome case with this exact pair has been published. Do not add a tryptophan supplement unless your prescriber advises it, and seek emergency care for agitation, tremor, fever, fast heartbeat, heavy sweating or muscle stiffness.
5-HTP is the body's direct building block for serotonin, so it adds to paroxetine's serotonin effect. The Paxil label names tryptophan, the amino acid the body turns into 5-HTP, among products that increase the risk of serotonin syndrome; it does not name 5-HTP itself, and no paroxetine case has been published. Do not combine them unless your prescriber directs it, and seek emergency care for agitation, tremor, fever, fast heartbeat, heavy sweating or muscle stiffness.
Contraindicated because of the risk of serotonin syndrome. The label requires at least 14 days between stopping an MAOI and starting paroxetine, and at least 14 days after stopping paroxetine before starting an MAOI.
A published case report describes a 20-year-old man taking fluoxetine (another SSRI) and lithium who had repeated episodes of serotonin syndrome needing hospital care, twice within hours of using high-THC cannabis oil or a vape pen. In lab studies, CBD and THC blocked CYP2D6, one of the enzymes that clears paroxetine, so they could raise paroxetine levels, though this has not been tested in people. Tell your prescriber about any cannabis or CBD use, and treat agitation, tremor, sweating, fever or a racing heart after use as an emergency.
Paroxetine increases the risk of bleeding, and the label says aspirin, NSAIDs, other antiplatelet drugs, warfarin and other anticoagulants may add to this risk. People on warfarin need closer clotting tests (INR) when paroxetine is started, changed or stopped. Ask your pharmacist before using an over-the-counter pain reliever.
The label says paroxetine blocks CYP2D6 irreversibly, lowering the level of tamoxifen's active metabolite (endoxifen). Some studies found lower tamoxifen effectiveness against breast cancer relapse and death with paroxetine, though others did not, and the label says prescribers should consider an antidepressant with little or no CYP2D6 blocking. Make sure your oncologist and prescriber both know you take these medicines.
Saffron may act partly through serotonin, which raises a theoretical concern about added serotonin effects. In a placebo-controlled trial of 160 adults already taking an antidepressant, adding a standardized saffron extract (14 mg twice daily) for 8 weeks improved clinician-rated depression scores without increasing antidepressant side effects, though self-rated scores improved no more than with placebo. Paroxetine was not studied separately. Discuss it with your prescriber before adding saffron.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
Warnings (3)
+ 5-htp
criticalParoxetine is a selective serotonin reuptake inhibitor (SSRI) that keeps serotonin active longer, and 5-HTP (5-hydroxytryptophan) is the direct building block the body turns into serotonin, so taking both can push serotonin activity too high and cause serotonin syndrome, a potentially life-threatening reaction. The Paxil label names tryptophan, the amino acid the body turns into 5-HTP, among serotonergic drugs that increase this risk; it does not name 5-HTP itself. No case with paroxetine and 5-HTP was found; the concern rests on the label, the shared mechanism and a published case of serotonin syndrome when 5-HTP was taken with sertraline, another SSRI.
+ st. john's wort
criticalParoxetine is an SSRI that raises serotonin by blocking its reuptake. St. John's wort independently raises serotonin and also speeds up drug-metabolizing enzymes and P-glycoprotein. Taken together, the additive serotonin effect can precipitate serotonin syndrome, a potentially life-threatening reaction, and the paroxetine label lists St. John's Wort among the drugs that raise this risk.
+ tryptophan
criticalParoxetine is a selective serotonin reuptake inhibitor (SSRI) that keeps serotonin active longer, and L-tryptophan is the amino acid the body turns into serotonin, so taking both can push serotonin activity too high. The Paxil label says combining paroxetine with other serotonergic drugs, naming tryptophan in the same list as St. John's wort, increases the risk of serotonin syndrome, a potentially life-threatening reaction. The label for Brisdelle, a low-dose paroxetine, adds that headache, nausea, sweating and dizziness have been reported when tryptophan was given to people taking paroxetine and says the combination is not recommended. No published case of serotonin syndrome with this exact pair was found; the rating follows the labels and matches the rating for tryptophan with sertraline, fluoxetine and venlafaxine.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Can I take St. John's wort with paroxetine?⌄
This page rates it a critical interaction. The Paxil label lists St. John's wort among products that raise the risk of serotonin syndrome with paroxetine. Talk to your prescriber before using it, and if you have been combining them, contact your prescriber rather than stopping anything on your own.
Is it safe to use cannabis or CBD while taking Paxil?⌄
Tell your prescriber about any use. A case report linked high-THC cannabis to repeated serotonin syndrome in a man taking another SSRI, and in lab studies CBD and THC blocked CYP2D6, an enzyme that clears paroxetine. This page rates the pair high.
Can I take saffron supplements with paroxetine?⌄
The concern is theoretical. Saffron may act partly on serotonin, but in a trial of adults already on antidepressants it did not increase side effects. This page rates the pair low severity. Ask your prescriber before starting it.
Can I take ibuprofen or aspirin with paroxetine?⌄
Ask your pharmacist or prescriber first. The label says aspirin and NSAIDs such as ibuprofen and naproxen add to paroxetine's bleeding risk, as do warfarin and other blood thinners.
What happens if I stop paroxetine suddenly?⌄
Stopping suddenly can cause discontinuation symptoms such as dizziness, irritability, nausea, sweating and electric-shock sensations. The label recommends a gradual reduction rather than abrupt stopping. Talk to your prescriber before making any change.
References by claim
major depressive disorder in adults
Cipriani et al., 2018 · PMC (2018) link
social anxiety disorder
Stein et al., 1998 · PubMed (1998) link
posttraumatic stress disorder (PTSD)
Marshall et al., 2001 · PubMed (2001) link
menopausal hot flashes (low-dose 7.5 mg)
Simon et al., 2013 · PubMed (2013) link
major depression in adolescents
Le Noury et al., 2015 · PMC (2015) link
Safety
Paxil (paroxetine) tablets prescribing information · DailyMed (FDA label) link
Interaction: St. John's wort (Hypericum perforatum)
Henderson et al., 2002 · PMC (2002) link
Interaction: L-tryptophan
Brisdelle (paroxetine) capsules prescribing information · DailyMed (FDA label) link
Interaction: 5-HTP (5-hydroxytryptophan)
Patel et al., 2017 · PMC (2017) link
Interaction: Cannabis (THC and CBD products)
Track Paroxetine with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
